PEGylated PLGA Nanopartieles as Tumor Eerosis Factor-α Receptor Blocking Peptide Carriers： Preparation, Characterization and Release in vitro

• Published in: Journal of Wuhan University of Technology. Materials science edition Vol. 22; no. 1; pp. 112 - 116
• Main Author: LIU Wei YANG Anshu LI Zhuoya XU Huibi YANG Xiangliang
• Format: Journal Article
• Language: English
• Published: 2007
• Subjects: PEG-PLGA纳米颗粒; 体外释放; 控制性缓释; 肿瘤坏死因子-α受体; 阻滞肽
• ISSN: 1000-2413; 1993-0437

To assess the merits of PEGylated poly （lactic-co-glycolic acid） （PEG-PLGA） nanoparticles as drug carriers for tumor necrosis factor-α receptor blocking peptide （TNFR-BP）, PEG-PLGA copolymer, which could be used to prepare the stealth nanoparticles, was synthesized with methoxypolyethyleneglycol, DL-lactide and glycolide. The structure of PEG-PLGA was confirmed with ^1H-NMR and FT-IR spectroscopy, and the molecular weight （MW） was determined by gel permeation chromatography. Fluorescent FITC-TNFR- BP was chosen as model protein and encapsulated within PEG-PLGA nanoparticles using the double emulsion method. Atomic force microscopy and photon correlation spectroscopy were employed to characterize the stealth nanoparticles fabricated for morphology, size with polydispersity index and zeta potential. Encapsulation efficiency （EE） and the release of FITC-TNFR-BP in nanopartieles in vitro were measured by the fluorescence measurement. The stealth nanoparticles were found to have the mean diameter less than 270 nm and zeta potential less than -20 mV. In all nanoparticle formulations, more than 45% of EE were obtained. FITC-TNFR-BP release from the PEG-PLGA nanoparticles exhibited a biphasic pattern, initial burst release and consequently sustained release. The experimental results show that PEG-PLGA nanoparticles possess the potential to develop as drug carriers for controlled release applications of TNFR-BP.